IMGN
ImmunoGen, Inc. [IMGN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IMGN Stock Summary
In the News
IMGN Financial details
Company Rating
Buy
Market Cap
8.73B
Income
-73.07M
Revenue
287.61M
Book val./share
1.95
Cash/share
2.11
Dividend
-
Dividend %
-
Employees
277
Optionable
No
Shortable
Yes
Earnings
28 Feb 2024
P/E
-122.93
Forward P/E
-
PEG
18.85
P/S
30.34
P/B
16
P/C
14.8
P/FCF
-43.68
Quick Ratio
5.47
Current Ratio
5.47
Debt / Equity
0.08
LT Debt / Equity
0.13
-
-
EPS (TTM)
-0.31
EPS next Y
-
EPS next Q
-
EPS this Y
-0%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-6.01%
Revenue last 5Y
15.11%
Revenue Q/Q
36.41%
EPS Q/Q
-721.12%
-
-
-
-
SMA20
3.33%
SMA50
40.91%
SMA100
-
Inst Own
60.92%
Inst Trans
0.7%
ROA
-9%
ROE
-22%
ROC
-0.12%
Gross Margin
99%
Oper. Margin
-28%
Profit Margin
-25%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.61-31.25
52W High
+0.76%
52W Low
+941.17%
RSI
84
Rel Volume
2.33
Avg Volume
8.29M
Volume
19.31M
Perf Week
5.85%
Perf Month
5.88%
Perf Quarter
-
Perf Half Y
110.76%
-
-
-
-
Beta
1.171
-
-
Volatility
0.59%, 0.69%
Prev Close
0.02%
Price
31.235
Change
0.02%
IMGN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.38 | 0.55 | 0.75 | 0.43 | 0.43 | |
| Net income per share | -1.2 | -0.82 | -0.38 | -0.88 | -0.88 | |
| Operating cash flow per share | -1.19 | -0.6 | -0.45 | -0.91 | -0.91 | |
| Free cash flow per share | -1.23 | -0.62 | -0.45 | -0.91 | -0.91 | |
| Cash per share | 1.87 | 1.19 | 1.67 | 1.08 | 1.08 | |
| Book value per share | 0.09 | -0.51 | 0.51 | 0.61 | 0.61 | |
| Tangible book value per share | 0.09 | -0.51 | 0.51 | 0.61 | 0.61 | |
| Share holders equity per share | 0.09 | -0.51 | 0.51 | 0.61 | 0.61 | |
| Interest debt per share | 0.01 | 0.3 | 0.27 | 0.08 | 0.08 | |
| Market cap | 671.74M | 757.87M | 1.14B | 1.88B | 1.26B | |
| Enterprise value | 411.55M | 608.49M | 866.22M | 1.62B | 998.12M | |
| P/E ratio | -4 | -6.21 | -17.04 | -8.44 | -5.64 | |
| Price to sales ratio | 12.48 | 9.21 | 8.59 | 17.3 | 11.56 | |
| POCF ratio | -4.04 | -8.58 | -14.45 | -8.19 | -5.47 | |
| PFCF ratio | -3.91 | -8.31 | -14.29 | -8.14 | -5.44 | |
| P/B Ratio | 56.25 | -9.96 | 12.68 | 12.08 | 8.07 | |
| PTB ratio | 56.25 | -9.96 | 12.68 | 12.08 | 8.07 | |
| EV to sales | 7.65 | 7.4 | 6.55 | 14.91 | 9.18 | |
| Enterprise value over EBITDA | -2.68 | -9.26 | -44.01 | -7.46 | -4.59 | |
| EV to operating cash flow | -2.47 | -6.89 | -11.02 | -7.06 | -4.34 | |
| EV to free cash flow | -2.4 | -6.67 | -10.89 | -7.02 | -4.32 | |
| Earnings yield | -0.25 | -0.16 | -0.06 | -0.12 | -0.18 | |
| Free cash flow yield | -0.26 | -0.12 | -0.07 | -0.12 | -0.18 | |
| Debt to equity | -0.78 | -0.35 | 0.27 | 0.1 | 0.1 | |
| Debt to assets | -0.03 | 0.11 | 0.07 | 0.04 | 0.04 | |
| Net debt to EBITDA | 1.7 | 2.27 | 13.72 | 1.19 | 1.19 | |
| Current ratio | 3.74 | 2.28 | 2.4 | 2.26 | 2.26 | |
| Interest coverage | -14.96 | -5.43 | -5.84 | -53.04 | -53.04 | |
| Income quality | 0.99 | 0.85 | 1.77 | 1.03 | 1.03 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.68 | 0.47 | 0.29 | 0.4 | 0 | |
| Research and developement to revenue | 3.23 | 1.39 | 0.87 | 1.96 | 1.96 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | |
| Capex to revenue | -0.1 | -0.03 | -0.01 | -0.01 | -0.01 | |
| Capex to depreciation | -0.71 | -0.71 | -0.44 | -0.77 | -0.77 | |
| Stock based compensation to revenue | 0.31 | 0.17 | 0.11 | 0.24 | 0.24 | |
| Graham number | 1.52 | 3.08 | 2.08 | 3.49 | 3.49 | |
| ROIC | -63.44 | 4.41 | -1.51 | -1.19 | -1.19 | |
| Return on tangible assets | -0.57 | -0.52 | -0.19 | -0.64 | -0.64 | |
| Graham Net | -0.15 | -0.89 | 0.17 | 0.41 | 0.32 | |
| Working capital | 192.19M | 98.82M | 171.53M | 153.28M | 153.28M | |
| Tangible asset value | 11.94M | -76.12M | 89.57M | 155.83M | 155.83M | |
| Net current asset value | -21.56M | -135.56M | 28.35M | 82.03M | 82.03M | |
| Invested capital | -0.78 | -0.35 | 0.27 | 0.1 | 0.1 | |
| Average receivables | 8.65M | 19.66M | 24.87M | 20.24M | 17.98M | |
| Average payables | 9.96M | 10.65M | 9.74M | 27.45M | 45.35M | |
| Average inventory | -7.75M | -24.6M | -31.54M | -7.1M | -6.39M | |
| Days sales outstanding | 81.84 | 120.89 | 62.07 | 60.32 | 60.32 | |
| Days payables outstanding | 23.86 | 31.66 | 30.38 | 94.06K | 94.06K | |
| Days of inventory on hand | -34.7 | -104.13 | -96.82 | 33.59K | -60.11K | |
| Receivables turnover | 4.46 | 3.02 | 5.88 | 6.05 | 6.05 | |
| Payables turnover | 15.3 | 11.53 | 12.01 | 0 | 0 | |
| Inventory turnover | -10.52 | -3.51 | -3.77 | 0.01 | -0.01 | |
| ROE | -14.06 | 1.6 | -0.74 | -1.43 | -1.43 | |
| Capex per share | -0.04 | -0.02 | -0.01 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.06 | 0.16 | 0.19 | 0.32 | 0.39 | |
| Net income per share | -0.31 | -0.23 | -0.16 | -0.02 | 0.11 | |
| Operating cash flow per share | -0.25 | -0.24 | -0.28 | -0.25 | 0.01 | |
| Free cash flow per share | -0.26 | -0.24 | -0.29 | -0.25 | 0 | |
| Cash per share | 1.22 | 1.08 | 0.78 | 2.17 | 2.11 | |
| Book value per share | 0.7 | 0.61 | 0.47 | 1.86 | 1.95 | |
| Tangible book value per share | 0.7 | 0.61 | 0.47 | 1.86 | 1.95 | |
| Share holders equity per share | 0.7 | 0.61 | 0.47 | 1.86 | 1.95 | |
| Interest debt per share | 0.07 | 0.06 | 0.06 | 0.29 | 0.17 | |
| Market cap | 1.21B | 1.26B | 993.98M | 4.97B | 4.56B | |
| Enterprise value | 918.47M | 1B | 806.99M | 4.47B | 4.03B | |
| P/E ratio | -3.88 | -5.35 | -6.13 | -292.56 | 37.11 | |
| Price to sales ratio | 78.82 | 30.65 | 19.93 | 59.78 | 40.24 | |
| POCF ratio | -18.87 | -20.96 | -13.48 | -74.49 | 1.65K | |
| PFCF ratio | -18.7 | -20.88 | -13.45 | -74.4 | 3.22K | |
| P/B Ratio | 6.81 | 8.1 | 8.15 | 10.13 | 8.13 | |
| PTB ratio | 6.81 | 8.1 | 8.15 | 10.13 | 8.13 | |
| EV to sales | 59.74 | 24.34 | 16.18 | 53.77 | 35.54 | |
| Enterprise value over EBITDA | -11.77 | -17.63 | -20.09 | -1.95K | 131.57 | |
| EV to operating cash flow | -14.3 | -16.64 | -10.95 | -66.99 | 1.46K | |
| EV to free cash flow | -14.17 | -16.58 | -10.92 | -66.92 | 2.85K | |
| Earnings yield | -0.06 | -0.05 | -0.04 | 0 | 0.01 | |
| Free cash flow yield | -0.05 | -0.05 | -0.07 | -0.01 | 0 | |
| Debt to equity | 0.09 | 0.1 | 0.12 | 0.16 | 0.08 | |
| Debt to assets | 0.05 | 0.04 | 0.05 | 0.11 | 0.06 | |
| Net debt to EBITDA | 3.76 | 4.57 | 4.66 | 218.16 | -17.41 | |
| Current ratio | 3.19 | 2.26 | 1.98 | 6.1 | 5.47 | |
| Interest coverage | -89.31 | -61.34 | -49.7 | -3.88 | 24.63 | |
| Income quality | 0.83 | 1.02 | 1.8 | 15.71 | 0.09 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.58 | 0 | 0.44 | 0 | |
| Research and developement to revenue | 3.85 | 1.42 | 1.04 | 0.6 | 0.42 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0 | -0.49 | |
| Capex to revenue | -0.04 | -0.01 | 0 | 0 | -0.01 | |
| Capex to depreciation | -1.42 | -0.58 | -0.47 | -0.18 | -3.2 | |
| Stock based compensation to revenue | 0.36 | 0.26 | 0.14 | 0.09 | 0.07 | |
| Graham number | 2.21 | 1.79 | 1.29 | 0.82 | 2.17 | |
| ROIC | -0.37 | -0.33 | -0.28 | -0.01 | 0.04 | |
| Return on tangible assets | -0.22 | -0.17 | -0.14 | -0.01 | 0.04 | |
| Graham Net | 0.52 | 0.41 | 0.23 | 1.56 | 1.55 | |
| Working capital | 226.77M | 153.28M | 99.62M | 478.29M | 601.57M | |
| Tangible asset value | 178.01M | 155.83M | 121.92M | 490.84M | 561.6M | |
| Net current asset value | 149.62M | 82.03M | 34.82M | 348.5M | 475.72M | |
| Invested capital | 0.09 | 0.1 | 0.12 | 0.16 | 0.08 | |
| Average receivables | 5.07M | 11.08M | 24.51M | 55.51M | 105.33M | |
| Average payables | 18.71M | 32.77M | 38.81M | 25.35M | 21.65M | |
| Average inventory | -10.02M | 8.1M | 8.41M | 1.92M | 4.36M | |
| Days sales outstanding | 24.53 | 39.3 | 56.03 | 86.55 | 103.7 | |
| Days payables outstanding | 4.28K | 23.19K | 4.64K | 1.83K | 1.04K | |
| Days of inventory on hand | 0 | 8.28K | 88.27 | 320.1 | 229.49 | |
| Receivables turnover | 3.67 | 2.29 | 1.61 | 1.04 | 0.87 | |
| Payables turnover | 0.02 | 0 | 0.02 | 0.05 | 0.09 | |
| Inventory turnover | 424K | 0.01 | 1.02 | 0.28 | 0.39 | |
| ROE | -0.44 | -0.38 | -0.33 | -0.01 | 0.05 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
IMGN Frequently Asked Questions
What is ImmunoGen, Inc. stock symbol ?
ImmunoGen, Inc. is a US stock , located in Waltham of Ma and trading under the symbol IMGN
What is ImmunoGen, Inc. stock quote today ?
ImmunoGen, Inc. stock price is $31.235 today.
Is ImmunoGen, Inc. stock public?
Yes, ImmunoGen, Inc. is a publicly traded company.
Company Profile
- Volume Average 8.29M
- Market Capitalization 8.73B
- Employee 277
- CEO Mr. Mark Joseph Enyedy
- Headquarters Waltham,MA,US
- IPO Date 1989-11-17
-
Website
https://www.immunogen.com 
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
